News + Events2019-02-14T10:49:18+00:00

Latest Press Releases

Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883

March 12th, 2018|

Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, today announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.

Load More Posts